Aarti Pharmalabs enterprise value

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
7,467————
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
4.28.554.394.063.1
686686396264214
8,148————
681677342170151
₹898.81————
2,9402,8102,3862,0211,772
23.3%24.4%16.6%13.1%12.1%
0.08×————
3.77×————
16.74×————
22.06×————
Reference items — trailing FY values
2,1611,8192,1151,8531,945
487369464386342
369265377313280
—262332216263
−147−147−70.517.6143
—−157−76.512.8138
—409402199120
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AARTIPHARM₹823.65

Aarti Pharmalabs Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSADVENZYMESAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹7,467 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————7,467.0
- Cash, Equiv & ST Investments63.194.054.38.54.2
+ Total Debt214.0264.1396.4685.6685.6
Enterprise Value————8,148.4
Net Debt (memo)150.9170.1342.1677.1681.4
EV per Share————898.81
Total Capital1,772.42,021.12,386.32,810.22,940.4
Total Debt/Total Capital12.0713.0716.6124.4023.32
Total Debt/EV————0.08
EV/Sales————3.77
EV/EBITDA————16.74
EV/EBIT————22.06
Reference Items — Trailing FY Values
Sales1,945.21,852.62,115.11,819.42,161.2
EBITDA342.0386.0464.4369.2486.7
EBIT279.5312.8377.5264.9369.4
Operating Cash Flow263.0216.4331.6261.9—
Free Cash Flow143.417.6-70.5-147.4-147.4
FCFF (free cash flow to the firm)137.912.8-76.5-157.5—
Capital Expenditure119.7198.8402.0409.4—
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.